Cibc Asset Management Inc Intellia Therapeutics, Inc. Transaction History

Cibc Asset Management Inc

  • $28 Billion
  • Q4 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022
SELL
$38.49 - $76.21 $120,550 - $238,689
-3,132 Closed
0 $0
Q4 2021

Feb 08, 2022
BUY
$100.76 - $138.36 $39,900 - $54,790
396 Added 14.47%
3,132 $370,000
Q3 2021

Nov 09, 2021
BUY
$132.37 - $176.78 $68,832 - $91,925
520 Added 23.47%
2,736 $367,000
Q2 2021

Aug 16, 2021
BUY
$60.88 - $161.91 $134,910 - $358,792
2,216 New
2,216 $359,000

Others Institutions Holding NTLA

# of Institutions
336
Shares Held
96.1M
Call Options Held
1.06M
Put Options Held
863K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $925M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Cibc Asset Management Inc Portfolio

Follow Cibc Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email